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Background: The bacterial cell wall and the enzymes that synthesize it are
targets of glycopeptide antibiotics (vancomycins and teicoplanins) and
β-lactams (penicillins and cephalosporins). Biosynthesis of cell wall
peptidoglycan requires a crosslinking of peptidyl moieties on adjacent glycan
strands. The D-alanine–D-alanine transpeptidase, which catalyzes this
crosslinking, is the target of β-lactam antibiotics. Glycopeptides, in contrast, do
not inhibit an enzyme, but bind directly to D-alanine–D-alanine and prevent
subsequent crosslinking by the transpeptidase. Clinical resistance to
vancomycin in enterococcal pathogens has been traced to altered ligases
producing D-alanine–D-lactate rather than D-alanine–D-alanine. 
Results: The structure of a D-alanine–D-lactate ligase has been determined by
multiple anomalous dispersion (MAD) phasing to 2.4 Å resolution. 
Co-crystallization of the Leuconostoc mesenteroides LmDdl2 ligase with ATP
and a di-D-methylphosphinate produced ADP and a phosphinophosphate
analog of the reaction intermediate of cell wall peptidoglycan biosynthesis.
Comparison of this D-alanine–D-lactate ligase with the known structure of DdlB
D-alanine–D-alanine ligase, a wild-type enzyme that does not provide
vancomycin resistance, reveals alterations in the size and hydrophobicity of the
site for D-lactate binding (subsite 2). A decrease was noted in the ability of the
ligase to hydrogen bond a substrate molecule entering subsite 2. 
Conclusions: Structural differences at subsite 2 of the D-alanine–D-lactate
ligase help explain a substrate specificity shift (D-alanine to D-lactate) leading
to remodeled cell wall peptidoglycan and vancomycin resistance in 
Gram-positive pathogens.
Introduction
Bacterial cell wall biosynthesis has been an attractive
target for antibacterial drugs, including the vancomycin
family of glycopeptide antibiotics and both the penicillin
and cephalosporin families of β-lactam antibiotics. Both of
these classes of antibiotics interdict the processing of pep-
tidoglycan (PG) intermediates bearing D-alanine–D-alanine
termini. The covalent crosslinking of adjacent peptide
strands in the PG layer provides mechanical strength to
the cell wall. The transpeptidase activity of bifunctional
transglycosylase/transpeptidase enzymes makes the cross-
links with displacement of the terminal D-alanine. 
β-Lactams inhibit the activity of the transpeptidases [1,2],
whereas vancomycins bind to the D-alanine–D-alanine PG
termini to block transpeptidase action [3]. Both drugs lead
to decreased crosslinking as the molecular basis of their
antibacterial activity.
The D-alanine–D-alanine moiety is preassembled by the
enzyme D-alanine–D-alanine ligase (Ddl) and then added
by the murF ligase to a tripeptide cosubstrate to yield a
pentapeptide PG intermediate terminating in
D-alanine–D-alanine [4]. The Ddl group of enzymes are of
special interest for two reasons. First, they are themselves
targets for antibiotics, although only D-cycloserine has
been developed for human use. Second, variants of the
Ddls are the agents of peptidoglycan remodeling in the
three major clinical phenotypes of vancomycin-resistant
enterococci (VRE). In the VanA (resistant to vancomycin
and teicoplanin) and VanB (resistant to vancomycin but
susceptible to teicoplanin) phenotypes the PG termini are
D-alanine–D-lactate, which has an ester instead of an amide
linkage, whereas in VanC the replacement is to a
D-alanine–D-serine [5]. The VanC-type D-alanine–D-serine
terminus has a tenfold reduced affinity for vancomycin,
the VanA-type and VanB-type depsipeptide terminus has
a much higher 1000-fold reduction of affinity. 
In a real sense, therefore, vancomycin resistance in VRE is
caused by a switch of D-alanine–D-alanine to D-alanine–D-X
ligases (where X is any amino acid) and the ability of the
VanA and VanB ligases to make depsipeptide is a true
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gain of function, which involves the selective activation
of the 2-OH of D-lactate as a nucleophile towards
D-alanine–OPO32– (Figure 1). 
When Ddls are compared with VanA, B and C by homol-
ogy searches, five subfamilies can be distinguished [6,7].
There are two Ddl subfamilies (DdlA and DdlB), a VanC-
type D-alanine–D-serine ligase subfamily and the two clus-
ters of D-alanine–D-lactate ligases. One D-alanine–D-lactate
subfamily is represented by the VanA and VanB ligases, as
well as the depsipeptide ligases of the vancomycin pro-
ducers [8]. The second D-alanine–D-lactate ligase subfam-
ily is found in the lactic acid bacteria, soil organisms with
natural resistance to vancomycin producers. This group
includes Leuconostoc mesenteroides [9], from which we have
previously purified the LmDdl2 ligase [10] and proved its
depsipeptide activity.
Deciphering the molecular basis of alanine–alanine
versus alanine–lactate production by the ligase subfami-
lies will require three-dimensional structures of com-
plexes with substrates or inhibitors. The first picture of a
D-alanine–D-alanine ligase emerged with the X-ray struc-
ture for the Escherichia coli DdlB in complex with ADP and
a tetrahedral analog of the reaction intermediate [11].
Among the findings from that work were the identification
of an omega loop closed over the intermediates and a
hydrogen-bonding network involving Tyr216 on that loop.
The Tyr216→Phe mutant was observed to have a small
but detectable gain of D-alanine–D-lactate depsipeptide
ligase activity, approximately 40-fold greater in catalytic
efficiency than the wild-type DdlB, perhaps reflecting an
initial step along the path to an efficient depsipeptide
ligase [12]. Relative to DdlB, both of the alanine–lactate
ligase subfamilies have substantially higher ratios of
alanine–lactate/alanine–alanine activity (Table 1). The
LmDdl2 ligase shows a ratio of 3000:1, whereas the VanA
ligase is tenfold better with a ratio of 30,000:1. In an effort
to understand these variations in function, we report here
the structure of a ligase from the second depsipeptide
ligase subfamily, the LmDdl2 ligase from the vanco-
mycin-resistant organism L. mesenteroides. 
Now available are crystal structures of three D-alanine–D-X
ligases, and a fourth is under investigation [13]. Each
ligase varies greatly in its production of depsipeptide
(Table 1), and thereby provides very different levels of
resistance to antibiotics of the glycopeptide family,
ranging from no resistance in wild-type organisms with the
DdlB-type ligase, through mid-level resistance in organ-
isms such as L. mesenteroides with the LmDdl2 ligase, to
high-level resistance in enterococcal pathogens using the
VanA ligase. In the crystal structures [11,14], all ligases are
complexed with similar dipeptidyl analogs of known prop-
erties and kinetics [10,15,16], so that comparison of
binding sites might explain the subtle differences in
ligand specificities. Here we focus on a comparison of the
LmDdl2 and DdlB ligases, with a brief inclusion of the
recently established VanA structure (D Roper and
G Dodson, unpublished observations).
Results and discussion
Crystal structure of the LmDdl2 ligase
LmDdl2 ligase is dimeric in the crystal (Figure 2a) as well
as in solution [10], with a noncrystallographic diad near
residues Ile85, Leu114, Leu127, Val132 and Leu142, most
of which are on α helices forming a hydrophobic interface.
LmDdl2 comprises three α + β domains (Figure 2b), a
folding motif first seen in glutathione synthetase [17,18].
The amide bond-forming site lies generally at the intersec-
tion of all three domains. The ATP-binding site is between
two antiparallel β sheets of the central and C-terminal
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Figure 1
Reactions catalyzed by ATP-requiring
D-alanine–D-X ligases. Common to both is the
phosphorylated D-alanyl intermediate. The
binding of vancomycin to the depsipeptide is
reduced 1000-fold relative to the dipeptide.
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Table 1
D-Alanine–D-lactate production by ligases.
Ligase Depsipeptide/dipeptide Increase
E. coli DdlB < 0.001 1
E. coli DdlB Y216F 0.04 40×
L. mesenteroides LmDdl2 3 3000×
S. toyoceansis DdlM 4* 4000×
Enterococcal VanA 30 30,000×
*From [40]. The structure of this ligase is not known.
domains and has the so-called ‘palmate’ [17] or ‘grasp’ [19]
motif now seen in other ATP-dependent enzymes [20,21].
Comparison of ligase foldings
Global similarity of the LmDdl2 and DdlB D-alanine–D-X
ligases is apparent in Figure 2b. LmDdl2 (and VanA)
contain a large 36-residue insertion in the N-terminal
domain that is not present in the smaller E. coli DdlB
enzyme (Figure 3). This insertion is unlikely to have an
influence on ligand specificity, however, as it is located
on the surface about 20 Å distant from the binding site for
the second ligand (subsite 2). The LmDdl2 ligase, the
largest of the three ligases, has a five-residue insertion in
the omega loop at position 247. LmDdl2 also has a much
longer C-terminal peptide that extends in the direction of
the other monomer in the dimer (Figure 2a). About half
of this 20-residue C-terminal extension is seen in the
electron-density map, and the invisible half is possibly
near the omega loop of the other monomer. C-terminal
disorder might be required for the movement of the
omega loop, which must open and close for ligand entry
and exit for each cycle of catalysis [22]. Consistent with
this idea is the finding that the more disordered C termi-
nus of monomer 1 lies near the disordered omega loop of
ligand-less monomer 2. This disorder might be the cause
of the high mosaicity that is observed in crystals.
With the LmDdl2 and DdlB sequences aligned according
to the crystallographic alignment in Figure 3, their similar-
ity is 44%. For the calculation of the root mean square
deviation (rmsd) of the two structures, 16 common
residues surrounding the ATP and ligand-binding sites
were chosen as a core set. The Cα atoms of the core
residues overlay rather closely (0.73 Å). When adding the
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Figure 2
Folding of the LmDdl2 ligase. (a) The LmDdl2 dimer viewed
perpendicular to the noncrystallographic diad axis (vertical). The
C-terminal helix (center) of each monomer extends to the other monomer.
ADP and phosphorylated analog 2 are observed only in monomer 1
(shown in red). Its omega loop is seen on the right-hand side. (b) Overlay
of LmDdl2 (red) and DdlB (yellow) based on minimization of Cα atoms in
16 core residues listed in the caption to Figure 3. The N terminus is at
the right of the figure. This figure was created using RIBBONS [41].
Figure 3
Amino acid sequences of the D-alanine–D-
alanine ligase from the ddlB gene of E. coli
[42] (top) and the D-alanine–D-lactate ligase
from the lmddl2 gene of L. mesenteroides [43].
Boxes contain segments clearly matched by
overlay of crystallographic structures. Important
spatially equivalent core residues in
DdlB/LmDdl2 are: Glu15/Glu16,
His63/His102, Lys97/Lys136, Lys144/Lys180,
Ser150/Ser186, Ser151/Ser187,
Glu180/Glu216, Lys181CO/Glu217CO,
Glu187/Glu224, Arg255/Arg301,
Asp257/Asp303, Glu270/Glu316,
Asn272/Asn318, Gly276/Gly322,
Ser281/Ser327 and Leu282/Leu328. The α
and β secondary structures are indicated by
boxes and arrows, respectively.
 DdlB MTDKIAVLLGGTSAEREVSLNSGAAVLAGLREGG IDAY 38  PVDPKEV                                  45
 LmDdl2 MTKKRVALIFGGNSSEHDVSKRSAQNFYNAIEATGKYEII 40  VFAIAQNGFFLDTESSKKILALEDEQPIVDAFMKTVDASD 80
 DdlB   DVTQLKSM 
 LmDdl2 PLARIHALKSAGDFDIFFPVVHGNLGEDGTLQGLFKLLDK 120 PYVGAPLRGHAVSFDKALTKELLTVNGIRNTKYIVVDPES 160
 DdlB FEKGLSDKQLAEIS NALQDALRLAFQHDEEVLIEKWLSG PEFTVAILG   EE 196
 LmDdl2 ANNW    SWDKIVAELGNIVFVKAANQGSSVGISRVTNA 196 EEYTEALSDSFQYDYKVLIEEAVNGARELEVGVIGNDQPL 236
 DdlB ILPSIRIQPSG     TFYDYEAKYLS DETQYFCPAGLE 230 ASQEANLQALVLKAWTTLGCKGWGRIDVMLDSDGQFYLLE 270
 LmDdl2 VSEIGAHTVPNQGSGDGWYDYNNKFVDNSAVHFQIPAQLS 276 PEVTKEVKQMALDAYKVLNLRGEARMDFLLDENNVPYLGE 316
 DdlB ANTSPGMTSHSLVPMAARQAGMSFSQLVVRILELAD     306                                      306
 LmDdl2 PNTLPGFTNMSLFKRLWDYSDINNAKLVDMLIDYGFEDFA 356 QNKKLSYSFVSLGEEKIGKFN                    377
Structure
GFQKVFIALHGRGGEDGTLQGMLELMGL 81  PYTGSGVMASALSMDKLRSKLLWQGAGLPVAPWVALTRAE 121
ALGLPVIVKPSREGSSVGMSKVVAE 160 
Cα atoms of all aligned residues (as defined in Figure 3) to
the core Cα atoms the rmsd increases to 1.4 Å. 
Transition-state analog
Co-crystallization of the LmDdl2 ligase with ATP and
1(S)-aminoethyl (2-carboxy-2(R)-methyl-1-ethyl) phos-
phinic acid 1 resulted in transfer of the γ-phosphate group
and production of a phosphorylated phosphinate 2
(Figures 4,5). Because dipeptide or depsipeptide forma-
tion is initiated by the attack of the first D-alanine
(D-alanine1) on the γ-phosphate of ATP to yield the
acylphosphate, the phosphorylated phosphinate is an
excellent analog of the presumed transition-state for the
ligation of the activated D-alanine with the second sub-
strate, either D-alanine or D-lactate. 
The phosphinophosphate analog 2 is known [23,24] to
inhibit wild-type Ddls with a very long half-life (in the order
of days). Its inhibitory effect on the VanA depsipeptide
ligase is much less striking [16]. For the LmDdl2 ligase, the
inhibition level is unmeasured but thought to be poor, and
capture of 2 in a crystal structure was not assured. In fact, we
find that only one monomer of the LmDdl2 dimer contains
the analog, and there is disorder around the empty binding
site of the second monomer. 
In the ordered monomer, the omega loop and a smaller
serine–serine loop (185–188) close over the cavity holding
ADP and 2. A hydrogen bond from Ser187 in the serine
loop to the backbone CO of Tyr255 in the omega loop is
maintained in all ligases (Table 2 and Figure 6). Because a
second hydrogen bond linking the two loops in DdlB is
absent in this LmDdl2 enzyme, where Phe261 replaces
Tyr216, one would expect that these loops might be more
‘floppy’ than in the DdlB enzyme. But this LmDdl2 struc-
ture and the structure of the Tyr216→Phe mutant of
DdlB [14] show that there is insignificant increase in loop
movement and indicate that the OH group is not required
for loop closure. 
Binding sites for ADP and D-alanyl phosphate
The geometry for ATP and D-alanine1 substrates in
LmDdl2 is similar to that in DdlB [11]. The adenine
group of the nucleotide is in a hydrophobic area with its
amine group hydrogen bonded to a sidechain of a con-
served glutamic acid (Glu216) and a backbone carbonyl
group (Glu217). The hydroxyl groups of the ribose
hydrogen bond with Glu224, and conserved lysines
Lys136 and Lys180 interact with the α- and β-phosphate
groups of ADP. The ammonium group of a lysine on the
omega loop (Lys260) joins two magnesium cations in
bridging the β- and γ-phosphate groups. In VanA,
however, this omega-loop lysine residue is absent and
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Figure 4
Co-crystallization of phosphinate 1 with the LmDdl2 ligase and ATP
produced ADP and the transition-state analogue 2. 
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Figure 5
The 2Fo–Fc electron-density map of ADP,
phosphorylated phosphinate 2 and
bridging magnesium ions in monomer 1 at a
contour level of 0.9σ. This figure was created
using CHAIN [36].
Structure
 N  N
replaced by two water molecules (D Roper and
G Dodson, unpublished observations). 
The α-ammonium group of the phosphorylated D-alanine1
is hydrogen bonded to the carboxylate group of the strictly
conserved Glu16 (Table 2 and Figure 6). Polarization of the
terminal P–O bond in the intermediate is accomplished by
hydrogen bonds from the sidechain amide of conserved
Arg301 and the backbone amide of Gly322 in an oxyanion
hole. Placement of the D-methyl group near Val19 and the
face of His102 helps define substrate chirality. 
Specificity for the second ligand
The D-alanine–D-X ligases must have the architecture
necessary to discriminate between zwitterionic D-alanine2
[7,25] and anionic D-lactate competing for subsite 2. Can
we explain why, in the LmDdl2 ligase, the binding affin-
ity of D-lactate is tenfold higher than that of D-alanine2
[10], and that D-lactate readily ligates with the activated
D-alanine1 even though D-lactate is a weaker nucleophile
than D-alanine2? 
We first address the greater affinity of subsite 2 for D-lactate
over D-alanine. External to the site is a positive sidechain,
Arg22 (Lys22 in VanA), which would be better than the
neutral Asn21 in DdlB in attracting the anionic lactate.
Internal groups surrounding subsite 2 include the con-
served residues Val19, Thr324 and Leu328. But two
changes in LmDdl2 will alter the hydrophobicity and size
of subsite 2 relative to DdlB ligase. Firstly, a buried Met326
is found in van der Waals contact with the second ligand,
replacing a solvent-exposed His280 in DdlB (Figure 7).
The -CH2–S–CH3 portion of Met326 will fill 55–60 Å3 [26]
of the binding cavity and could restrict the binding of the
zwitterionic amino acid [25] in favor of the slightly smaller
lactate anion. (The NH3+ and OH groups are estimated to
differ in volume by 10–12 Å3). And secondly, Tyr216 in
DdlB is replaced by the more hydrophobic Phe261 in
LmDdl2. Together, these alterations in cavity size and
hydrophobicity might contribute to the tenfold greater
binding for lactate over alanine2 in LmDdl2. Opposing this
trend, however, is the fact that the hydrophobic sidechain
of Leu328, although it is  common to LmDdl2 and DdlB,
has rotated approximately 3 Å away from the C-terminal
carboxylate, having been replaced by a water molecule. 
In searching for enzymic influences on the nucleophilicity
of the second ligand, we see that the local binding interac-
tions of the C terminus of the analog indeed differ from
those observed in DdlB (Table 2, Figures 6,7). Subsite 2
lies at the N terminus of the 327–335 helix, the dipole of
which might assist alignment of the ligand [11]. Unlike the
situation in the DdlB complex, however, in LmDdl2 the
secondary structure of this helix is somewhat irregular.
The carboxylic acid group of 2 is not as strongly hydrogen
bonded to the hydroxyl group of conserved Ser327, and,
significantly, no carboxylate hydrogen bond exists to the
backbone amide of Leu328. Structurally, the longer dis-
tances in LmDdl2 result from an expansion of the ligation
site along the dipeptide axis. Thus, distances from Glu16
or Ser186 (residues near the N-terminal alanine1) to Ser327
or Leu328 (residues near the C-terminal ligand) are longer
in LmDdl2 by 0.5–1.4 Å. Given the prepositioning of the
N-terminal D-alanine1, the C-terminal carboxylic acid
group of the second ligand falls short of one of the two
potential hydrogen-bonding groups on the enzyme.
Instead, a water molecule bridges between a carboxylate
oxygen atom and the backbone amide of Leu328. For an
incoming lactate molecule, therefore, weaker hydrogen
bonding by its carboxylate group would increase the nucle-
ophilicity of the α-hydroxyl group, and hence facilitate its
attack on the activated carbon of alanine1 in the first site.
Catalytic residues?
A plausible catalytic base was never identified in the DdlB
ligase [11,15]. Based on the crystal structure, the
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Table 2
Distances in binding sites*.
Distance LmDdl2 DdlB–Y216F DdlB
A1 2.9 3.0 2.8
A2 2.8 2.8 2.6
B1 3.1 3.0 3.2
B2 3.0 3.0 3.1
C1 2.6 2.6 2.3
C2 4.0 3.1 2.8
C3 2.8 2.5 2.4
C4 3.3 – –
D1 2.7 3.0 2.8
D2 3.1 2.9 3.4
E 2.9 2.8 2.5
*See Figure 6.
Figure 6
Schematic showing the distances listed in Table 2. Residues Tyr255,
Lys260 and Phe261 are on the omega loop. Gly322NH and Arg301
form an oxyanion hole.
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Tyr216→Phe mutant of the DdlB enzyme was made and
found to exhibit a small amount of new depsipeptide
activity [12] (Table 1). The markedly more active
LmDdl2 ligase in fact contains phenylalanine (Phe261) at
the corresponding spatial position (Figure 7), but other
changes exist as well, the importance of which can be
evaluated by site-directed mutagenesis. For example, a
buried glutamic acid Glu226 in LmDdl2 has replaced a
threonine in DdlB. Glu226 reaches toward the analog 2,
forming a weak water-bridged hydrogen bond with the
acyl phosphate group and another with the C-terminal car-
boxylate group of 2. Within 2.7 Å of Glu226 is a buried
histidine residue, His243. Although the catalytic involve-
ment of this histidine is unknown, it is interesting that the
histidine–glutamate pair is only found in the ligase with
moderate depsipeptide activity. The inactive DdlB ligase,
its weakly acitve Tyr216→Phe mutant, and the highly
active VanA ligase all have unreactive residues at these
two positions. The recent crystal structure of VanA
(D Roper and G Dodson, unpublished observations)
shows that a much better-positioned histidine His244
replaces Phe216 of DdlB and Phe261 of LmDdl2, an
alignment unforeseen in earlier sequence matches [7,11].
Biological implications
Bacteria are rapidly changing in response to heavy antibi-
otic use, either by means of microbial selection, mutations,
or transfer of genetic material from drug-resistant strains
to susceptible strains [27]. The steady spread of resistance
to the penicillins is well documented [28]. Vancomycin,
the backup antibiotic for Gram-positive infections that do
not respond to penicillin therapy, is increasingly used in
the treatment of methicillin-resistant Staphylococcus
aureus. With the discovery of vancomycin resistance in
Enterococcus faecium in 1988, there is growing concern
that the plasmid-borne resistance will be transferred to
Staphylococcus aureus [29,30]. 
The wild-type D-alanine–D-alanine ligases have long
been good antibiotic targets [31], in that they are
present in all bacteria, are necessary for growth, and
are absent from humans. The newer D-alanine–D-lactate
ligases such as VanA and VanB, found in highly van-
comycin-resistant gram-positive pathogens, might have
arisen from the chromosomal D-alanine–D-lactate
ligases present in producing organisms such as Strepto-
myces toyocaensis or in the intrinsically resistant lactic
acid organisms such as Leuconostoc mesenteroides. A
comparison of three-dimensional structures of D-amino
acid ligases might help establish ancestry and reveal
enzymic changes leading to modification of cell wall
peptidoglycan and glycopeptide resistance.
Materials and methods
Strains and chemicals
E. coli strains BL2(DE3) and B834(DE3) were obtained from
Novagen (Madison, WI). Culture media was obtained from Difco Lab-
oratories (Detroit, MI). Amino acids, nucleotides, dithiothreitol (DTT),
ampicillin, and buffers were from Sigma Chemical Co. (St. Louis,
MO). Isopropyl-thio-β-D-galactoside (IPTG) was purchased from
Bachem Biosciences (Torrance, CA) and polyethyleneglycols (PEGs)
were from Hampton Research (LaGuna Niguel, CA). Phosphinate 1
was a generous gift from PA Bartlett and BA Ellsworth (University of
California, Berkeley). 
Overexpression of wild-type and selenomethionine LmDdl2
LmDdl2 ligase was overexpressed as described previously [10]. For
overexpression of the selenomethionine-substituted LmDdl2 ligase,
pLmDdl2 was transformed into the E. coli met auxotroph expression
strain B834(DE3). The corresponding strain was grown overnight in
21 ml of medium, which was 5% (v:v) Luria broth and 95% M9 medium
supplemented with 1 mg l–1 thiamine, 1 g l–1 glucose, 489 mg l–1
MgSO4.7H2O, 14.7 mg l–1 CaCl2, 7.5 mg l–1 FeSO4, 100 µg l–1 ampi-
cillin, 50 mg l–1 each of 18 amino acids (excluding methionine and cys-
teine), and 50 mg l–1 selenomethionine [32]. The cells were spun
down, resuspended in M9 media (supplemented as above), and used
to inoculate 2 l of supplemented M9 media. The culture media was
incubated at 37°C until A595 = 0.8. IPTG at a final concentration of
0.5 mM was added to induce lmddl2 gene expression, and the culture
was further incubated for 5 h at 30°C.
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Figure 7
Overlay of phosphorylated phosphinate 2 in
the binding site in LmDdl2 (red) and DdlB
(orange). LmDdl2 residues are numbered.
Distances are given in Table 2. This figure
was drawn using MOLSCRIPT [44].
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Protein purification
Purification of wild-type LmDdl2 ligase was performed as previously
described [10]. Selenomethionine LmDdl2 was purified similarly except
that degassed 50 mM HEPES at pH 7.2, 5 mM MgCl2, 1 mM EDTA,
200 mM KCl, and 1 mM DTT was used for cell lysis and subsequent
purification steps, yielding 60 mg of purified protein.
Mass spectrometry analysis
Wild-type and selenomethionine LmDdl2 were analyzed by electro-
spray mass spectrometry at the Mass Spectrometry Facility of Harvard
University (Cambridge, MA). For wild-type LmDdl2, which contains six
methionine residues in a total of 377, the measured mass is 41,686
Da. The measured mass for selenomethionine LmDdl2 is 41,947 Da.
The 261 mass difference is between that expected for five and six sele-
nium substitutions per molecule.
Crystallization
Both wild-type and selenomethionine-substituted LmDdl2 protein could
be crystallized under similar conditions. Crystals were grown at room
temperature by the vapor equilibrium method. The drop contained
protein at 3.5 mg ml–1 in 15% PEG 8000 (or mPEG 5000) for the
selenoprotein), 0.1 M ammonium sulfate, 50 mM NaCl (0 mM for
selenoprotein), 2.4 mM DTT for selenoprotein, 1 mM MgCl2, 3 mM ATP
(AMP–PNP for the selenoprotein), 3 mM phosphinate, in 50 mM MES
buffer at pH 6.5. The reservoir contained 30% PEG or mPEG and
0.2 M ammonium sulfate in 0.1 M MES buffer. Diamond-shaped plates
appeared after one to two weeks. Separation of glycol and salt phases
occurred in most drops after one month. Two monoclinic forms grew
under these conditions. Form 1, the subject of this paper, had unit-cell
dimensions 118.2 × 90.8 × 82.1 Å, β = 92.1° (100 K) in space group
C2 with two monomers in the asymmetric unit (VM = 2.6 Å3 Da–1). Form
2, also with two monomers in the asymmetric unit, had cell dimensions
167.2 × 64.7 × 112.3 Å, β = 112.3° in C2 (VM = 3.5 Å3 Da–1). The two
monoclinic forms often grew in the same drop, with form 1 appearing
two to three weeks after form 2. Both forms diffracted to approximately
the same resolution, 2.2–2.4 Å. 
X-ray data from the native LmDdl2 crystal
A form 1 crystal was immersed in the 30% PEG holding solution contain-
ing 25% MPD for 4 min prior to being loop-mounted and flash cooled to
100°K in a liquid nitrogen gas stream. Single-wavelength (0.908 Å) data
collection was performed at MacCHESS station A1 at the Cornell High
Energy Synchrotron Source, Ithaca, NY. A CCD area detector (Area
Detector Systems Corp.) was used in 1k × 1k mode at a distance of
80 mm from the crystal. A total of 204° of data, made from 1° phi oscilla-
tions of 20 sec each, was processed using the HKL programs [33]. Cal-
culated mosaicity was high (1.9°) and overall completeness was only
82% to 2.38 Å resolution. The Rmerge (on intensities) was 7.2% (Table 3).
X-ray data from the selenomethionine LmDdl2 crystal
A form 1 seleno-crystal was immersed in the PEG holding solution con-
taining 22% MPD for 45 sec and flash cooled to 100°K in a liquid nitro-
gen gas stream. MAD data were collected by the reverse-beam method
at three wavelengths (0.9500 Å remote, 0.9786 Å peak and 0.9789 Å
edge) at station ×12c at NSLS at Brookhaven National Laboratory. A
CCD area detector (Brandeis B4) 344 mm from the crystal recorded
2k × 2k images for a 1° phi oscillation. Count times were 50 sec per
image. Data were collected at the edge wavelength over a 36° wedge
of phi, then recollected at the peak and remote wavelengths until 107°
of data were recorded. This process was repeated at phi plus 180°.
Intensities were indexed and scaled by HKL [33]. Poor crystal mosaic-
ity (0.8°) reduced the completeness of the three data sets to 55–63%
at 2.4 Å resolution. Rmerge values were 4.8%, 5.8% and 5.2% at the
three wavelengths (Table 3). 
Structure solution
A search for a molecular replacement solution using DdlB structures
(2DLN, 1IOV or 1IOW) as models was not successful. In spite of poor
data completeness for the selenomethionine crystal, the structure was
determined by the MAD method using version 1.15 of the program
SOLVE [34]. The Patterson analysis found 10 of the 12 possible sele-
nium atoms (11 expected from mass spectrometry). The average sele-
nium occupancy and B factor were 0.95 and 43 Å2, respectively. The
successful heavy-atom solution had a Z-score of 76.3. The resulting
electron-density map at 2.5 Å resolution had a standard deviation in the
local rms density equal 0.34, and the correlation of rms density in neigh-
boring regions was 0.40. The unmodified MAD-phased map was much
better than an earlier three-derivative multiple isomorphous replacement
(MIR) map (figure of merit = 0.58 at 3 Å resolution). The MAD map
showed 95% of the backbone chain for monomer 1 and density for its
ligands, and about 90% of the chain of monomer 2. Missing in monomer
2 was density for the omega loop (245–266) near the catalytic site, pos-
sibly because of the absence of ligands in the binding site of this
monomer (see below). Density-modified maps based on solvent flatten-
ing or twofold symmetry averaging were also examined, but did not
improve the density of the omega loop in monomer 2. The sequence
[35] of the 377-residue protein was manually fitted using the programs
CHAIN [36] and FRODO [37]. The 2 molecules formed a noncrystallo-
graphic dimer (Figure 2a) and were fitted independently.
Structure refinement 
Simulated annealing refinement was initiated at 1,500 K with X-PLOR
version 3.8.5.1 [38]. Data from 8.0–2.5 Å with Fobs greater than 2σ(F)
were used, with 4% of the data excluded for calculating Rfree [39]. Indi-
vidual B factors were initially set to 15 Å2 for protein atoms. Water mol-
ecules were excluded from this early refinement, as were ligands and
several residues from the N and C termini of each molecule. Monomer
2 also lacked 22 residues in the omega loop. Examination of 2Fo–Fc
and Fo–Fc maps of the dimer allowed the fitting of ADP and phos-
phinophosphate 2 in the binding site of monomer 1, but not in
monomer 2. Various annealing and energy minimization protocols failed
to bring up density for the ligands or omega loop of monomer 2. 
Final cycles of refinement used all 2.38 Å data from the native crystal,
which had better completeness in the higher resolution shells. For a
model that includes 360 residues in monomer 1 (3–362), 347 residues
in monomer 2 (numbered 402–644 and 667–770), one ADP and one
phosphinophosphate 2 ligand in monomer 1, and 213 water molecules
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Table 3
X-ray data for native and selenomethionine crystals*.
Data set Native Se remote Se peak Se edge
λ(Å) 0.9080 0.9500 0.9786 0.9789
f′ – –2.6 –8.3 –8.2
f′′ – 3.7 6.0 3.0
Observations 94,338 49,290 47,414 48,959 
(4374) (189) (435) (646)
Unique refls 30,564 22,828 22,997 24,156 
(1738) (163) (394) (589)
Completion 0.82 0.55 0.60 0.63 
(0.47) (0.024) (0.062) (0.093)
Av I/σ(I) 11.0 14.3 12.4 13.1 
(3.8) (2.3) (2.1) (2.0)
Rmerge† 0.072 0.048 0.058 0.052 
(0.21) (0.44) (0.20) (0.28)
Ranom‡ – 0.053 0.064 0.058
Rdisp§ – 0.035 vs. 0.031 vs. 0.046 vs. 
peak edge remote
*Data for high-resolution shells in parentheses: native 2.48–2.38 Å;
selenomethionine 2.44–2.30 Å. †Rmerge = Σ | Iav–Ii |/Σ Ii, where Iav is the
average of all individual observations, Ii. ‡Ranom = Σ | F+–F–|/Σ |Fav | for
anomalous differences, where Fav is the average of Friedel amplitudes at
a single wavelength. §Rdisp = Σ | Fλi–Fλj | / Σ |Favλ | for dispersive
differences, where Favλ is the average amplitude at two wavelengths.
(B factors < 60 Å2), the resulting crystallographic R factor is 0.184 for
all F > 0 data from 100–2.38 Å (27,948). The Rfree value is 0.257.
Deviations of the protein model from ideality are 0.008 Å and 1.4° for
covalent bonds and angles, respectively. The electron density of ADP
and 2 is seen in Figure 5. 
Accession numbers
Atomic coordinates have been deposited in the Protein Data Bank
(with the accession code 1EHI) at Rutgers University.
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